Table 1

Clinical characteristics of the subjects

P value

Group(N)

ACLF(31)

CLF(26)

NC(12)

ACLF vs CLF

ACLF vs NC

CLF vs NC


Gender(m/f)

28/3

22/4

7/5

Agea

40.0(5.5)

47.5(7.5)

48(4.75)

.039

.013

.694

ALT(IU/L) a

93(70.5)

45.5(26.8)

19.0(4.87)

.061

.00

.000

Tbil(╬╝mol/L) a

303.4(201.8)

37.15(21.44)

16.4(1.91)

.000

.000

.001

CHOL

(mmol/L) a

1.01(0.63)

2.2(0.3)

3.8(0.76)

.000

.000

.000

INRa

2.50(0.48)

1.63(0.34)

0.96(0.06)

.000

.000

.000

HBeAg (+/-)

9/22

4/22

NT

.225

HBVDNA(+/-)

23/8

18/8

NT

.679

MELD scorea

26.49(3.76)

11.39(3.84)

0(0)

.000

.000

.000


NT, not detected; ALT, alanine aminotransferase; CHOL, cholesterol; Tbil, total bilirubin; INR, international normalized ratio; HBeAg, hepatitis B e antigen; anti-HBe, hepatitis B e antibody; HBVDNA, hepatitis B deoxyribonucleic acid load; MELD, Model for End-stage Liver Disease.

aThe medians (interquartile range) of age, ALT, Tbil, CHOL, INR and MELD for each group are shown

Niu et al. BMC Immunology 2011 12:47   doi:10.1186/1471-2172-12-47

Open Data